Publications &
Presentations
In our pursuit of scientific advancement we are committed to sharing our acquired knowledge through actively publishing our data in peer-reviewed journals and academic conferences. We aim to provide a deeper understanding through extensive study and analysis on ileal bile acid transporter (IBAT) inhibition, for both the scientific and patient communities.
Research Updates
Featured Presentations & Publications
Brelovitug Monotherapy Achieved 100% Virologic Response in Patients with Chronic Hepatitis D: On Treatment Week 48 Phase 2 Study Results
Agarwal, et al. Presentation, AASLD 2025.
Volixibat leads to improvements in fatigue and sleep for adults with primary biliary cholangitis: Data from VANTAGE
Kowdley, et al. Oral Presentation, AASLD 2025.
Maralixibat, an ileal bile acid transporter inhibitor, reduces cholestatic pruritus in PSC: Real-world experience
Martins, et al. Poster Presentation, AASLD 2025.
Evaluation of MRM-3379, a PDE4D Inhibitor, in a Mouse Model of Fragile X Syndrome
Carter, et al. Poster Presentation, FXS-NDD 2025.
Volixibat for the treatment of cholestatic pruritus in primary biliary cholangitis: an adaptive, randomized, placebo-controlled phase 2B trial (VANTAGE): 28-week interim analysis
Heneghan, et al. Oral Presentation, EASL 2025.
Real-world Use of Maralixibat in Biliary Atresia: A Case Series
Dilwali, et al. Poster Presentation, AASLD 2024.
Latest Research Updates
Filter by topic
- SELECT
- Show all
- Smith Lemli Opitz Syndrome (SLOS)
- Cerebrotendinous Xanthomatosis (CTX)
- Cholbam
- Fragile X Syndrome (FXS)
- Chronic Hepatitis Delta Virus (HDV)
- Alagille syndrome
- Biliary atresia
- Health economics and outcomes research
- IBAT inhibition
- LIVMARLI (maralixibat)
- Patient-reported outcomes validation
- Primary biliary cholangitis
- Primary sclerosing cholangitis
- Progressive familial intrahepatic cholestasis
- Volixibat
Until a relevant regulatory agency has approved a Mirum product for a specific disease or population, any scientific presentations regarding such disease or population are not to be considered instruction on the appropriate use of Mirum products or clinical candidates.
